Nabriva's pneumonia drug meets main goal in late-stage study

(Reuters) - Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading.